Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronado Biosciences Inc.

This article was originally published in Start Up

Executive Summary

Coronado Biosciences in-licenses and develops cancer drugs. One of its candidates is apogossypol, an inhibitor of Bcl-2 proteins that play a role in programmed cell death--a process that cancer cells manage to circumvent. Also in the start-up's pipeline: a less-toxic anthracycline and an agent that activates natural killer cells against residual cancer cells following treatment.

You may also be interested in...



Start-Up Previews

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Targeted Cancer Therapeutics," features profiles of Coronado Biosciences, Emiliem and SynDevRx. Plus these Start-Ups Across Health Care: Activaero, Chakshu Research, Myomo and Valor Medical.

Emiliem Inc.

Virtual discovery company Emiliem is focused on kinase inhibitors for cancer. The company's K-STAR (Kinase Structure-Target Activity Relationship) platform incorporates new evidence from the scientific and patent literature into a model of kinase enzymes which play key roles in cell functions. Emiliem currently has candidates that target mTOR, Akt, and other kinase pathways; each drug candidate inhibits multiple kinases.

Targeted Cancer Drugs

In the past decade, a new paradigm has emerged in the form of drugs that target the genetic abnormalities that cause a normal cell to become cancerous. These targeted therapies are the fastest growing segment in the oncology market, and are poised to garner a respectable share of a global anti-cancer market projected to reach $70 billion by the end of this decade. Currently, there are 24 such compounds in Phase III clinical trials. The complex challenges in developing these drugs haven't deterred start-ups from entering the fray.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091549

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel